- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 103,360 | 20.09.24 15:19:44 | -0,880 | -0,84% | 0,000 | 0,000 | 104,240 | 103,360 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 1.023,000 | 20.09.24 08:21:03 | -12,000 | -1,16% | 0,000 | 0,000 | 1.023,000 | 1.023,000 |
